Hummingbird Bioscience Website, Blog & Press Pages

Hummingbird Bioscience Website, Blog & Press Pages - aVenture Research

Library

hummingbirdbioscience.comCrawled Nov 2, 2026

Product

6 pages

AACR 2023: HMBD-501 – a novel Fc engineered, exatecan-based next-generation HER3-targeting Antibody-Drug Conjugate (ADC) shows robust tolerability and efficacy in pre-clinical solid tumor models/hmbd-501-a-novel-fc-engineered-exatecan-based-next-generation-her3-targeting-antibody-drug-conjugate-adc-shows-robust-tolerability-and-efficacy-in-pre-clinical-solid-tumor-models
We have developed HMBD-501, a novel anti-HER3 ADC with (i) a high-affinity Fab, which can bind to HER3 in the presence or absence of its ligand NRG1, (ii) an engineered Fc-domain to avoid FcgR binding and potential toxicities, and (iii) site-specific conjugation to a next generation cleavable linker and exatecan-based payload.
ASCO 2023: A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors/hmbd-002-a-phase-1-first-in-human-clinical-trial-of-hmbd-002-an-igg4-monoclonal-antibody-targeting-vista-in-advanced-solid-tumors
HMBD-501/hmbd-501
HMBD-501 combines Hummingbird Bioscience’s systems biology approach with advanced bioconjugation to create a potential best-in-class HER3-ADC.
Patients/patients
Hummingbird Bioscience invests in understanding cancer biology to develop antibody therapeutics tailored for patient benefit.

Blog

6 pages

Building an Explainable Toxicity Knowledge Graph/building-an-explainable-toxicity-knowledge-graph
Hummingbird Bioscience is building an explainable toxicity graph, developed in collaboration with LynxKite, supported by NVIDIA accelerated computing.
Cancer Research, Volume 77, Issue 13 Supplement, AACR Journals: HMBD-001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of Erb/cancer-research-volume-77-issue-13-supplement-aacr-journals-hmbd-001-a-novel-anti-erbb3-antibody-with-a-unique-mechanism-of-action-effectively-inhibits-tumor-growth-in-pre-clinical-models-of-erb
Gastric cancer is the second-leading cause of cancer mortality in Asia. ErbB3, a cell-surface receptor tyrosine kinase, is overexpressed in ~60% of metastatic gastric cancer patients, correlating with poorer survival.
Cancer Research, Volume 77, Issue 13, AACR Journals: HMBD-002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tu/cancer-research-volume-77-issue-13-aacr-journals-hmbd-002-a-novel-neutralizing-antibody-targeting-a-specific-epitope-on-the-co-inhibitory-immune-checkpoint-receptor-vista-displays-potent-anti-tu
V-domain immunoglobulin (Ig)-containing suppressor of T-cell activation (VISTA), also called PD1 homolog (PD1H), is a co-inhibitory immune checkpoint receptor expressed mainly on hematopoietic cells, including myeloid-derived suppressor cells and antigen-presenting cells, and at lower levels on CD4+ and CD8+ T cells and Foxp3 Tregs.
Cancer Research, Volume 78, Issue 13, Supplement, AACR Journals: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD-002, a no/cancer-research-volume-78-issue-13-supplement-aacr-journals-integrative-immune-profiling-of-syngeneic-tumor-models-provides-predictive-immune-signatures-for-treatment-response-with-hmbd-002-a-no
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells with immune-suppressive activity. Their accumulation in the tumor microenvironment contributes to resistance to immunotherapy, and they highly express VISTA, a co-inhibitory checkpoint regulator.

Press

6 pages

Hummingbird Bioscience Announces first patient dosed in Phase I clinical trial of HMBD-501 in advanced HER3-expressing solid malignancies/hummingbird-bioscience-announces-first-patient-dosed-in-phase-i-clinical-trial-of-hmbd-501-in-advanced-her3-expressing-solid-malignancies
Hummingbird Bioscience today announced that the first patient has been dosed in a Phase I clinical trial of HMBD-501 for the treatment of patients with advanced HER3-expressing solid malignancies
Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers/hummingbird-bioscience-announces-first-patient-dosed-in-phase-ii-trial-of-hmbd-001-and-cetuximab-in-advanced-squamous-cell-cancers
The advancement of HMBD-001 in clinical development demonstrates translation of Hummingbird Bioscience’s AIMM platform from drug design through clinical development and patient selection
Hummingbird Bioscience Appoints Dr. James Garner as President/hummingbird-bioscience-appoints-dr-james-garner-as-president
Hummingbird Bioscience appoints Dr. James Garner as President. Dr. Garner will join the leadership team and work alongside Piers Ingram, CEO.
Hummingbird Bioscience Closes US$25 Million Investment With Series B Extension/hummingbird-bioscience-closes-us25-million-investment-with-series-b-extension
Hummingbird Bioscience, a biotherapeutics company specializing in antibody discovery, raised $25 million in an extended Series B funding round.

Careers & Hiring

1 page

Join us/careers
Hummingbird Bioscience employs a team focused on engineering next-generation therapies for precision medicine.

About

1 page

About Us/about-us
The company is a clinical-stage biotechnology firm using its Rational Antibody Discovery (RAD) platform to develop precision therapeutics for cancer and autoimmune diseases.

Contact

2 pages

Contact/contact
Partnering/partnering
Hummingbird Bioscience collaborates with global biopharma and research institutes to advance its clinical therapies and expand its antibody-drug conjugate and antibody platforms.

Homepage

1 page

Homepage/
Hummingbird Bioscience is leading a bold new way of engineering precision biotherapeutics that can define the future of precision medicine.

Privacy

1 page

Coverage

8 items

Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancershummingbirdbioscience.com/hummingbird-bioscience-announces-first-patient-dosed-in-phase-ii-trial-of-hmbd-001-and-cetuximab-in-advanced-squamous-cell-cancers/
Hummingbird Bioscience begins dosing the first patient in a Phase II trial combining its experimental therapy **HMBD-001** with **cetuximab** for advanced squamous cell cancers. The study, labeled **HMBD-001-103**, marks the progression of HMBD-001 into Phase II clinical development. The company focuses on developing treatments for diseases with unmet medical needs.
Sep 2026Hummingbird Bioscience | Precision Medicine. Precision Therapies.News article
Hummingbird Bioscience Appoints Dr. James Garner as Presidenthummingbirdbioscience.com/hummingbird-bioscience-appoints-dr-james-garner-as-president/
Hummingbird Bioscience names **Dr. James Garner** as its new President. He will lead the company’s biotherapeutics development alongside CEO Piers Ingram, focusing on medicines for diseases with unmet medical needs. Garner joins Hummingbird’s executive team to advance its pipeline of transformative treatments.
Sep 2026Hummingbird Bioscience | Precision Medicine. Precision Therapies.News article
Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awardsfinance.yahoo.com/healthcare/articles/hummingbird-bioscience-wins-apac-trailblazer-090000216.html
Hummingbird Bioscience wins the APAC Trailblazer Award at the 2026 Nebius AI Discovery Awards. The company was chosen from 647 global applicants by an independent judging panel. The award recognizes innovation in AI-driven solutions within the Asia-Pacific region.
Jul 2026Yahoo FinanceNews article
Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancieshummingbirdbioscience.com/hummingbird-bioscience-announces-first-patient-dosed-in-phase-i-clinical-trial-of-hmbd-501-in-advanced-her3-expressing-solid-malignancies/
Hummingbird Bioscience begins dosing the first patient in a Phase I clinical trial of its experimental therapy **HMBD-501** for patients with advanced **HER3-expressing solid tumors**. The trial, identified as **NCT06956690**, targets malignancies where HER3 overexpression drives disease progression. The company specializes in developing biotherapeutics for unmet medical needs.
Jan 2026Hummingbird Bioscience | Precision Medicine. Precision Therapies.News article